FDA Cites Manufacturing Issues for Cytisinicline - Top-Institutions - MDSpire

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

  • By

  • Kathryn Wighton

  • June 22, 2026

  • 3 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Pharmacology
    • Tobacco Research

  • #2

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, California

    Key Differentiators

    • Pharmacology
    • Clinical Research

  • #3

    Stanford University
    Stanford University

    Stanford, California

    Key Differentiators

    • Pharmacology
    • Medical Technology

  • #4

    University of South Carolina
    University of South Carolina

    Columbia, South Carolina

    Key Differentiators

    • Pharmacology
    • Public Health

  • #5

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Pharmacology
    • Clinical Research

Original Source(s)

FDA Cites Manufacturing Issues for Cytisinicline

  • by Kathryn Wighton

  • June 22, 2026

Related Content

Histological transformation into pulmonary sarcomatoid carcinoma from lung adenosquamous carcinoma after radical resection of EGFR gene Exon-21 L858R mutation: a case report and literature review

Can Consumer Wearables Support PASC Monitoring?

Heart rate monitoring and atrial fibrillation detection had the strongest supporting evidence, but investigators found limited evidence for broader outpatient self-monitoring applications.

Editorial: Artificial intelligence advancing lung cancer screening and treatment